1University of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
2German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
3Center for Human Genetics, KU Leuven, Leuven, Belgium
4Center for Cancer Biology, VIB, Leuven, Belgium.
Correspondence: Andreas Engert (. e-mail: firstname.lastname@example.org).
Citation: Eichenauer DA, Cools J, Engert A. Introducing the HemaSphere Controversies Series. HemaSphere, 2019;00:00. http://dx.doi.org/10.1097/HS9.0000000000000296
The authors have no conflicts of interest to disclose.
Received August 27, 2019
Accepted September 2, 2019
Online date: September 27, 2019
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0